Drug intelligence / Profile preview

MTP58

Development stage: Unknown
Lead developer: Medytox
Administration: Intradermal

Overview

MTP58 is an investigational medical device developed by Medytox, categorized as a dermal filler. It is specifically designed for the treatment and correction of fine lines. Currently in the discovery stage, MTP58 is part of Medytox's expanding portfolio of aesthetic medical devices, which includes their established hyaluronic acid filler line, Neuramis. The device is intended for injection into the dermal layers of the skin to provide mechanical volume and smooth out superficial wrinkles, restoring a more youthful appearance.

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on MTP58.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTP58.

Explore the full profile